Most Read Articles
20 Jun 2020
The Lundbeck Neuroscience Symposium was held at Sofitel KL Damansara over 2 days, with extensivediscussions on the management of various mental illnesses. The second day of the symposiumaddressed the topic of schizophrenia management, focusing on treatment goals, the rationale forpartial dopamine D(2) receptor agonism and the use of long-acting injectable (LAI) antipsychotics topromote adherence.
Pearl Toh, 5 days ago
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
4 days ago
Patients with psoriatic arthritis (PsA) often suffer from liver abnormalities, which are associated with higher body mass index (BMI), daily consumption of alcohol, more severe disease, and some therapies, according to a recent study.
Christina Lau, 3 days ago

Pembrolizumab in combination with chemotherapy significantly improves progression-free survival (PFS) vs chemotherapy alone in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), results of the KEYNOTE-355 study have shown.

Rituximab for systemic sclerosis safely improves skin fibrosis

06 Jun 2019

Treatment with rituximab in patients with systemic sclerosis (SSc) is relatively safe and produces improvements in skin but not lung fibrosis, a study has shown.

Researchers used data from the European Scleroderma Trials and Research (EUSTAR) network and identified 254 SSc patients (median age, 51 years; 71 percent female) treated with rituximab. They assessed the safety of the drug and its effect on skin fibrosis improvement, lung fibrosis worsening and steroids use.

In the cohort, rituximab was indicated for lung involvement in 58 percent of patients and for skin involvement in 32 percent. After a median follow-up of 2 years, the majority (70 percent) of patients did not develop any side effects.

An analysis comparing the 254 rituximab-treated SSc patients with 9,575 propensity-score matched patient controls showed rituximab treatment to be associated with a higher likelihood of skin fibrosis improvement (22.7 vs 14.03 events per 100 person-years; odds ratio [OR], 2.79, 95 percent CI, 1.47–5.32; p=0.002).

On the other hand, there were no significant between-group differences observed in rates of forced vital capacity (FVC) >10 percent (OR, 1.03, 0.55–1.94; p=0.93) or in carbon monoxide diffusing capacity (DLCO) <70 percent (OR, 1.68, 0.68–4.2; p=0.27).

Compared with controls, rituximab-treated patients were more likely to stop or reduce steroids (OR, 2.34, 1.56–3.53; p<0.0001). Furthermore, patients who received mycophenolate mofetil concomitantly tended to have better outcomes than those who received rituximab alone (delta FVC: OR, 3, 0.66–5.35; p=0.012) and controls (OR, 5.22, 0.83–9.62; p=0.019).

The study was limited by its observational design, according to researchers, adding that the potential stabilization of lung fibrosis by rituximab has to be addressed in a randomized trial.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
20 Jun 2020
The Lundbeck Neuroscience Symposium was held at Sofitel KL Damansara over 2 days, with extensivediscussions on the management of various mental illnesses. The second day of the symposiumaddressed the topic of schizophrenia management, focusing on treatment goals, the rationale forpartial dopamine D(2) receptor agonism and the use of long-acting injectable (LAI) antipsychotics topromote adherence.
Pearl Toh, 5 days ago
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
4 days ago
Patients with psoriatic arthritis (PsA) often suffer from liver abnormalities, which are associated with higher body mass index (BMI), daily consumption of alcohol, more severe disease, and some therapies, according to a recent study.
Christina Lau, 3 days ago

Pembrolizumab in combination with chemotherapy significantly improves progression-free survival (PFS) vs chemotherapy alone in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), results of the KEYNOTE-355 study have shown.